Low-dose naltrexone as a treatment for chronic fatigue syndrome.
BMJ Case Rep. 2020.
PMID: 31911410
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 2 |
Search Results
17 results
Results by year
Citations
3
articles
found by citation matching
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
J Transl Med. 2024.
PMID: 38970055
Free PMC article.
Review.
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Front Immunol. 2021.
PMID: 34326841
Free PMC article.
Search results
Page 1
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502.
BMJ Case Rep. 2020.
PMID: 31911410
Free PMC article.
Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. ...This series of three case reports compiled by people with long-term ill-health due to chro …
Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with …
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
J Transl Med. 2024 Jul 5;22(1):630. doi: 10.1186/s12967-024-05412-3.
J Transl Med. 2024.
PMID: 38970055
Free PMC article.
Review.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). ...TRPM3 dysfunction in NK cells can be improved by naltrexone in vitro and ex vivo, whi …
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomat …
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
BMJ Open. 2024 May 13;14(5):e085272. doi: 10.1136/bmjopen-2024-085272.
BMJ Open. 2024.
PMID: 38740499
Free PMC article.
INTRODUCTION: A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post- …
INTRODUCTION: A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present wit …
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.
Clin Ther. 2024 Mar;46(3):e101-e106. doi: 10.1016/j.clinthera.2023.12.009. Epub 2024 Jan 23.
Clin Ther. 2024.
PMID: 38267326
PURPOSE: Treatments for myalgic encephalomyelitis and chronic fatigue syndrome can be adapted for post-COVID-19 condition. Our aim was to compare treatments in patients from our post-COVID-19 clinic. ...Both fatigue and pain were improved in patients t …
PURPOSE: Treatments for myalgic encephalomyelitis and chronic fatigue syndrome can be adapted for post-COVID-19 conditi …
Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series.
Cureus. 2023 Aug 13;15(8):e43426. doi: 10.7759/cureus.43426. eCollection 2023 Aug.
Cureus. 2023.
PMID: 37706146
Free PMC article.
Introduction In recent years, low-dose naltrexone has emerged as a novel off-label therapy for many chronic conditions including postural orthostatic tachycardia syndrome (POTS), however, there is little evidence for its efficacy. Methods In thi …
Introduction In recent years, low-dose naltrexone has emerged as a novel off-label therapy for many chronic cond …
Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up.
Cureus. 2025 May 10;17(5):e83824. doi: 10.7759/cureus.83824. eCollection 2025 May.
Cureus. 2025.
PMID: 40491623
Free PMC article.
Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and often further somatic symptoms. ...I report a patient with severe FMS who did not respond to conventional therapy …
Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbanc …
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Front Immunol. 2021 Jul 13;12:687806. doi: 10.3389/fimmu.2021.687806. eCollection 2021.
Front Immunol. 2021.
PMID: 34326841
Free PMC article.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multi-systemic chronic condition of unknown aetiology classified as an immune dysfunction syndrome and neurological disorder. ...Based on the benefits reported by pati …
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multi-systemic chronic condition o …
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.
Int J Pharm Compd. 2018 May-Jun;22(3):252-256.
Int J Pharm Compd. 2018.
PMID: 29878893
Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive dysfunction. ...At the doses required for fibromyalgia treatment, naltrexone needs to be compounded, and no data currently exists re …
Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive …
Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy.
Cureus. 2019 Mar 11;11(3):e4225. doi: 10.7759/cureus.4225.
Cureus. 2019.
PMID: 31123647
Free PMC article.
Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. ...This report describes a case of a 47-year-old female with suspected Sjogren's based on long-standing …
Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resultin …
The Use of Naltrexone in Low Doses Beyond the Approved Indication.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 8-2015.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 8-2015.
PMID: 28510411
Free Books & Documents.
Review.
Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, cancer, inflammatory bowel disease, chronic fatigue syndrome, and amyotrophic …
Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclero …
Cite